 (-10 (-24, -3)
asthma had poorer average scores for subjective sleep quality than the normal subjects (median paired difference 11 (95% confidence limits 041, 2 3)). Objective overnight sleep quality was also worse in the asthmatic patients, who spent more time awake at night (median difference 51 (95% CL 8-1, 74) minutes), had a longer sleep onset latency (12 (10, 30) minutes), and tended to have less stage 4 (deep) sleep (-33 (-58, 4) minutes). Daytime cognitive performance was worse in the patients with nocturnal asthma, who took a longer time to complete the trail making tests (median difference 62 (22, 75) seconds) and achieved a lower score on the paced serial addition tests (-10 (-24, -3) ). Mean daytime sleep latency did not differ significantly between the two groups (2 (-3, 7) minutes). It is concluded that hospital outpatients with stable nocturnal asthma have impaired sleep quality and daytime cognitive performance even when having their usual maintenance asthma treatment.
Eighty per cent of patients with asthma are woken at least occasionally by nocturnal wheeze and cough,' and many patients with severe stable asthma are woken by symptoms virtually every night.23 Previous work suggested that such sleep disruption in patients with nocturnal asthma may be further compounded by the use of oral theophylline.4
Even short term sleep deprivation may result in impaired daytime cognitive performance.56 We postulated that the long term sleep disruption resulting from a combination of nocturnal airway narrowing and drug treatment might cause impairment of daytime cognitive performance in patients with nocturnal asthma. We have therefore measured daytime cognitive performance, nocturnal sleep quality and objective daytime sleepiness in stable patients with nocturnal asthma.
Methods
We studied 12 patients who were clinically stable but had nocturnal asthma, who had had no hospital admissions or change in medication for at least one month before the study, and 12 normal subjects. Nocturnal asthma was defined as a mean overnight fall in peak expiratory flow rate of at least 15% in association with at least one awakening a week due to wheezing, coughing, or breathlessness, during a two week run in period, in a patient with known asthma. Each patient was matched with a normal subject for age (± 2 years) and premorbid intelligence on the basis of the national adult reading test7 (scores matched to + 5 in the national adult reading test). This has been extensively validated as a test of premorbid intellect.89 Normal subjects were selected from respondents to a newspaper advertisement requesting healthy volunteers for asthma research. All said that they were non-smokers, were taking no medication, and had no history of respiratory illness. None of the patients or normal subjects had any history of psychiatric illness or sleep related illness or had used sedative medication.
Patients and normal subjects kept a diary card throughout the study period (two weeks) on which they recorded the number of awakenings each night and assigned a score to the subjective sleep quality on a scale from 0 ("very refreshing sleep") to 5 ("didn't sleep at all"). In addition, patients recorded on their diary cards peak expiratory flow measurements (best of three attempts) on four occasions during the day, and during the night if they woke. Normal subjects had their peak expiratory flow (best of three attempts) recorded before and after their sleep studies. Throughout the study patients continued to take all their usual maintenance asthma drugs (inhalers: beta agonist and inhaled corticosteroid-all 12 patients, ipratropium-8, cromoglycate-2; oral medication: theophylline-6, beta agonist-6, corticosteroid-5 latency (p = 0 08), but none of these individual factors had a significant independent influence on time spent awake at night or sleep onset latency. Theophylline intake did not have a significant independent influence on any ofthe variables found to show impairment in the asthmatic subjects (PASAT B: p = 0-81; trail making B: p = 0-44; time spent awake at night: p = 0-38; or sleep onset latency: p = 0 77. Discussion Asthma is a common condition and the prevalence is increasing.2' Most asthmatic patients wake with nocturnal symptoms from time to time and patients with more severe asthma may experience asthma symptoms most nights. This study shows that patients who are clinically stable and have nocturnal asthma have poorer daytime cognitive performance and poorer subjective and objective sleep quality than do normal subjects. These abnormalities occurred despite the fact that the number of self reported nocturnal awakenings was no different in patients and normal subjects.
We have shown deficits in patients with nocturnal asthma by comparison with age and intellect matched normal subjects in tests that examine (1) concentration and attention (paced auditory serial addition test) and (2) visual scanning, hand-eye coordination, and mental set flexibility (trail making). These tests are demanding and require information to be stored in working memory while new information is assimilated and responses are made. Detecting small differences in cognitive ability is difficult because most people can call on reserve capacity, even when fatigued. Nevertheless, the paced auditory serial addition and trail making tests, by demanding close attention, mental manipulation and quick thinking, did detect differences between the two groups in the present study. A test of memory (auditory verbal learning test), which was not timed, and tests of driving and reaction time, which are mentally less demanding, did not separate the patients and controls. Our findings extend those of a study that reported that children with "severe asthma" had poorer psychomotor function than non-asthmatic children,24 though that study contained no objective measurement ofthe severity ofairflow obstruction, no characterisation of nocturnal asthma, and no sleep recordings.
Possible reasons for the observed deficits in daytime cognitive performance in asthmatic patients include sex differences between patients and controls, sleep deprivation, drug treatment, and depressed mood. Patients and controls were rigorously matched for age and premorbid intelligence, both ofwhich influence psychometric performance. As such matching was difficult to achieve we decided not to match also for sex, as there is no evidence that this affects psychometric performance. Specifically, there is no evidence that gender affects performance in either the paced auditory serial addition'5 or the trail making tests. 23 Short term sleep deprivation may lead to demonstrable impairment of daytime cognitive performance.56 Furthermore, intermittent disruption of sleep for two nights, amounting to no more than one hour's sleep loss a night, has been found to impair cognitive performance to much the same extent as one night of sleep deprivation.24 The cumulative effect of sleep disruption over many nights could therefore account for the deficit in daytime cognitive performance in the patients with nocturnal asthma.
Theophylline has been suspected of causing impaired daytime cognitive performance in asthmatic children,2-27 but its effect on performance is controversial28 29 and inadequately documented in adults. Only five of our 12 patients had detectable plasma theophylline concentrations. Most ofthe important differences between the two groups remained when these five pairs of subjects were excluded from the analysis, and multiple linear regression did not show a significant independent influence of theophylline on psychometric performance. Furthermore, a recent study showed no acute or medium term effect of therapeutic doses of theophylline on the psychometric performance of healthy adults (the test battery included trail making and paced auditory serial addition tests).
Psychomotor retardation is a well recognised feature of clinical depression and, though none of our asthmatic patients had ever been recognised as clinically depressed, their higher scores on the hospital anxiety and depression scale suggest a possible mood effect on their performance. The hospital anxiety and depression score was not, however, a significant independent predictor of either paced auditory serial addition test scores or trail making times according to multiple linear regression analysis: regression of the paired differences in paced auditory serial addition scores and trail making time against paired differences in hospital anxiety and depression scores showed that when the anxiety and depression score difference was zero the estimated mean PASAT score and trail making time differences were significant (PASAT B: p < 0-01); trail making B: p < 0-03).
We have shown for the first time that patients with stable asthma and nocturnal symptoms have impaired sleep quality while continuing to take their usual maintenance antiasthma drugs.
Montplaisir and colleagues'0 showed that eight patients who had attacks of nocturnal asthma while having a sleep recording had less efficient sleep and spent more time awake after the onset of sleep than age matched normal subjects-or they themselves after two weeks of intensive treatment for their asthma. In this study, however, bronchodilators were withheld for six hours before bedtime; patients with asthmatic attacks were asked to perform forced expiratory manoeuvres during the recording night before and after nebulised salbutamol (a process taking "10 to 15 minutes"), assessment of sleep quality was made with subjects wearing full polysomnography equipment, and sleep times were not standardised. Kales et al3132 found that asthmatic children had a shorter total sleep time and spent less time in stage 4 sleep than non-asthmatic children. In these studies, however, (1) bronchodilators were again withheld for at least six hours before bedtime; (2) a group of retrospective control subjects was used; (3) asthma was documented only by symptoms and not by objective measurements of airway obstruction; and (4) sleep times were not standardised. We have found from a single night's recording, without withholding treatment, less efficient sleep, more time spent awake at night, and a trend towards less stage 4 sleep in patients with stable nocturnal asthma than in normal subjects of the same age.
Drug treatment may also affect sleep quality. In nine clinically stable patients with nocturnal asthma theophylline reduced the total sleep time, increased the time spent in drowsiness and light sleep, and reduced the amount of slow wave (deep) sleep4 despite reducing nocturnal bronchoconstriction. Administration of an oral beta agonist to patients with asthma did not improve sleep quality despite a reduction in overnight bronchoconstriction. '4 Depression can cause sleep disturbance. Very depressed patients will typically have a shorter REM latency, a higher proportion of wakefulness and light sleep, and less slow wave sleep with earlier final awakening than normal subjects."4 Although seven of our 12 patients had hospital anxiety and depression scores compatible with mild depression, the number was not significantly different from that in our normal subjects, and there was no relation between hospital anxiety and depression scores and daytime performance.
We conclude that stable hospital outpatients with nocturnal asthma, taking their usual maintenance medication, have impaired daytime cognitive performance and impaired subjective and objective sleep quality by comparison with age and intellect matched normal subjects.
